TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01646671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 200 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
Study: NCT02074735

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active comparator in appearance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
Study: NCT00559897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]FLT
Description: Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography
Description: Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
Study: NCT03705039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Ultrasound Treatment
Description: Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
Study: NCT03223103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Poly-ICLC 100mcg per peptide per dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Description: synthetic long peptides (SLP) as vaccine substrate
Study: NCT00578773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Intervention type: DEVICE
Group type: OTHER
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study: NCT01646034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, thiotepa, and cyclophosphamide
Description: tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
Description: * chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine
Study: NCT03755765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BB-12
Description: Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
Study: NCT04536844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)
Description: An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional prescheduled follow-up
Description: Patients will be followed in the outpatient clinic by prescheduled follow-up
Study: NCT00652457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10 mg BID x 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: 10 mg BID x 3 months
Study: NCT03636490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Stress Intervention
Description: Participant will be shown a series of words for five minutes and a research coordinator will ask him/her to name the color of each (Stroop Color-Word Conflict Task). Then, for another five minutes, the participant will be asked to count backwards out loud by sevens starting from 1,000 (Mental Arithmetic Task). The research assistant will ask the participant to work as quickly and accurately as possible for both tasks.
Study: NCT04097379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LRX712
Description: LRX712 intra-articular injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LRX712
Description: LRX712 intra-articular injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra-articular injections
Study: NCT03698682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: One tablet per day for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: One tablet per day for 7 days.
Study: NCT03898817

Intervention type: OTHER
Intervention: taking of cutaneous cells
Description: Taking of cutaneous cells by biopsy Sample of blood
Study: NCT03139656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Clarification
Description: This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning
Description: Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined
Description: Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit.
Study: NCT04360824

Intervention type: DRUG
Group type: OTHER
Intervention: Intermediate dose thromboprophylaxis
Description: 2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
Study: NCT04360824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care thromboprophylaxis
Description: Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
Study: NCT00968110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Dosing table established for omalizumab
Study: NCT02772068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Istaroxime
Description: Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT03918980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Study: NCT02772068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT05115994

Intervention type: DEVICE
Intervention: Continous positive airway pressure

Intervention type: DEVICE
Intervention: Continous positive airway pressure

Intervention type: DEVICE
Intervention: Continous positive airway pressure
Study: NCT03353428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC-CTLs
Description: 2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
Study: NCT03920397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation
Description: The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation
Description: The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
Study: NCT02443298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo for risankizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Monoclonal IgG antibody
Study: NCT03850886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacinamide Oral Tablet
Description: Nature's Life Niacinamide 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidiabetic
Description: Metformin or Sulphonylurea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiabetic
Description: Metformin or Sulphonylurea
Study: NCT03608800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
Study: NCT03905057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries 2 (with active applicator)
Description: Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dornier Aries 2 (with sham applicator)
Description: Sham ESWT - No shockwave administered
Study: NCT02139163

Intervention type: OTHER
Intervention: Cohort Study
Study: NCT01132144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
Study: NCT01686087

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Booster Sessions of EX/RP
Description: 45 minute EXRP booster sessions each month

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Monthly Booster Sessions of EX/RP
Description: 45 minute EXRP booster sessions each month

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visits with MD and independent evaluators
Description: All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Visits with MD and independent evaluators
Description: All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
Study: NCT01369290

Intervention type: DRUG
Intervention: Venlafaxine
Description: 75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.

Intervention type: DRUG
Intervention: bupropion
Description: 150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.

Intervention type: DRUG
Intervention: escitalopram
Description: 10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.

Intervention type: OTHER
Intervention: Psychotherapy
Description: Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.

Intervention type: DRUG
Intervention: Duloxetine
Description: 30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Study: NCT02030691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous airway positive pressure (nCPAP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous airway positive pressure (nCPAP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high frequency percussive ventilation (nHFPV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high frequency percussive ventilation (nHFPV)
Study: NCT04487977

Intervention type: OTHER
Intervention: Survey
Description: Answering a survey on airway management in COVID-19 patients
Study: NCT03952533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dav
Description: Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
Study: NCT02381535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02709265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin
Description: single aerosolized dose
Study: NCT03918980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Study: NCT02709265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin
Description: single aerosolized dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin
Description: single aerosolized dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin
Description: single aerosolized dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin
Description: single aerosolized dose
Study: NCT02097420

Intervention type: DEVICE
Group type: OTHER
Intervention: Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve
Description: Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
Study: NCT04156256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123-CD33 cCAR T cells
Description: CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
Study: NCT04004923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar hysteroscopy
Description: Unipolar resectoscopes are used in this group and the distention fluid is mannitol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar hysteroscopy
Description: Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
Study: NCT03918980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules will be administered in parts 1,2, 4 and 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules will be administered in parts 1,2, 4 and 6.
Study: NCT03759223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Problem-Solving Training (E-PST)
Description: E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Messages (HLM)
Description: Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Problem-Solving Training (E-PST) (non-randomized)
Description: E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.